Neurocrine Biosciences (NASDAQ:NBIX) PT Raised to $153.00

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its price objective hoisted by The Goldman Sachs Group from $134.00 to $153.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm presently has a “buy” rating on the stock. The Goldman Sachs Group’s price target indicates a potential upside of […]

Related Keywords

Eiry Roberts ,Robertw Baird ,Neurocrine Biosciences ,Jude Onyia ,Goldman Sachs Group ,Nasdaq ,Raymond James Financial Services Advisors Inc ,Neurocrine Biosciences Inc ,Securities Exchange Commission ,Red Spruce Capital ,Sunbelt Securities Inc ,Metis Global Partners ,Neurocrine Biosciences Company Profile ,Get Free Report ,Exchange Commission ,Financial Advisors ,Spruce Capital ,James Financial Services Advisors ,Global Partners ,Neurocrine Biosciences Daily ,Nasdaq Nbix ,Nbix ,Medical ,64125c10 ,Boost Price Target ,The Goldman Sachs Group Inc ,